OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: C2N Diagnostics

4 Projects | 3 Researchers | $9,797,840 Invested

2024

C2N Diagnostics

Joel Braunstein, MD, MBA

Validation of a Mass Spectrometry-Based Clinical Lab Workstation and Global Scale-up of Precivity(TM) In-Vitro Diagnostic Testing

  • Funding Amount: $7,025,121
  • Organization Type: Biotechnology/For Profit
  • Program: Diagnostics Accelerator
  • Status: Active

2020

C2N Diagnostics

Kevin Yarasheski, PhD

Clinical Validation and Accreditation for Plasma Aß42/Aß40 as a Biomarker for Alzheimer’s Disease Pathology

  • Funding Amount: $2,225,237
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Target: zzAbeta
  • Status: Active

2010

C2N Diagnostics

Tim West, PhD

Preclinical development of plasma based AD diagnostic test using a combination of antibody administration and stable isotope labeling kinetics

  • Funding Amount: $247,482
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Status: Closed

2008

C2N Diagnostics

Tim West, PhD

Validation and Optimization of an Immunoprecipitation Assay for Amyloid Beta from Human Cerebrospinal Fluid Using Novel Antibodies

  • Funding Amount: $300,000
  • Organization Type: Biotechnology/For Profit
  • Program: Biomarkers
  • Status: Closed